Associated Papers
An in-depth exploration of four heterogeneity structure-based EGFR mutation subgroups in Chinese non-small cell lung cancer.
Yu Y et al.
Bmc Pulmonary Medicine, 2025
40611150 (PubMed )
Supplement: 12890_2025_3774_MOESM1_ESM.xlsx › Sheet1
Resistance to BRAF inhibition explored through single circulating tumour cell molecular profiling in BRAF-mutant non-small-cell lung cancer.
Mezquita L et al.
British Journal of Cancer, 2024
Structure-based classification predicts drug response in EGFR-mutant NSCLC.
Robichaux JP et al.
Nature, 2021
34526717 (PubMed )
Supplement: 41586_2021_3898_MOESM1_ESM.pdf
Mutation Spectrum of EGFR From 21,324 Chinese Patients With Non-Small Cell Lung Cancer (NSCLC) Successfully Tested by Multiple Methods in a CAP-Accredited Laboratory.
Mao L et al.
Pathology Oncology Research : Por, 2021
Genetic heterogeneity of actionable genes between primary and metastatic tumor in lung adenocarcinoma.
Kim EY et al.
Bmc Cancer, 2016
26782967 (PubMed )
Supplement: 12885_2016_2049_MOESM1_ESM.xlsx › Sheet1
Select a paper to view details